CoChat

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Open access
Blom, Dirk J., Averna, Maurizio R., Meagher, Emma A., du Toit Theron, Hendrik, Sirtori, Cesare R., Hegele, Robert A., Shah, Prediman K., Gaudet, Daniel, Stefanutti, Claudia, Vigna, Giovanni B., Larrey, Dominique, Bloedon, LeAnne T., Foulds, Pamela, Rader, Daniel J., Cuchel, Marina · 2017 · Circulation
Cited by 140

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

omozygous familial hypercholesterolemia is a genetic disorder characterized by low-density lipoprotein (LDL)-receptor dysfunction, markedly elevated levels of LDL-cholesterol (LDL-C) and premature atherosclerosis.Patients are often poorly responsive to conventional lipid-lowering therapies that upregulate LDL-receptor expression. 1 Lomitapide inhibits microsomal triglyceride transfer protein, which lipidates nascent apolipoprotein (apo)B-containing lipoproteins.In a pivotal 78-week openlabel trial, lomitapide, titrated to the maximal tolerable dose, decreased LDL-C by 50% at the end of the efficacy phase (week 26) in patients with homozygous familial hypercholesterolemia. 2 The principal adverse events included gastrointestinal disturbances, hepatic enzyme elevations, and increased liver fat.Here we provide additional long-term efficacy and safety data, including an exploratory analysis of the potential metabolic consequences of hepatic fat accumulation from an extension trial (NCT00943306).Patients continued on lomitapide at the maximally tolerated dose until transition to commercial or compassionate lomitapide.Lipid-lowering therapies, including apheresis, could be modified at the investigator's discretion if LDL-C was <100 mg/dL.Both studies received institutional review board and regulatory approval, and all participants provided informed consent.Significance of the percent changes from baseline was assessed using a mixed linear model; correlations were assessed with Pearson correlation.Nineteen (mean age, 30.4 years; 10 male/9 female) of the 23 patients who completed the pivotal trial enrolled in the extension trial, and 17 completed week 126 (78 weeks pivotal + 48 weeks extension) assessments (primary efficacy end point).Three patients discontinued prematurely (relocation, elevated transaminases and excess alcohol, sudden cardiac death).The median lomitapide dose remained mostly consistent at 40 mg (range, 20-60 mg) from week 36 in the pivotal study to week 282 in the extension trial.Overall, the median treatment duration with lomitapide across both trials was 5.1 years (range, 2.1-5.7 years).Among the 17 patients who completed week 126, LDL-C decreased from 356±127 mg/dL at baseline to 189±120 mg/dL at week 126, a mean percent change of -45.5% (95% confidence interval [CI], -61.6 to -29.4; P<0.001).LDL-C reduction was maintained for the duration of the extension trial (P<0.001; Figure , A).From baseline through week 246, a total of 14 (74%) patients achieved LDL-C <100 mg/dL, and 11 (58%) patients achieved LDL-C <70 mg/dL on at least 1 occasion.LDL-C reduction was independent of residual LDL-receptor functionality.The most common adverse events reported were gastrointestinal, including diarrhea, nausea, dyspepsia, and vomiting.For most drug-related adverse events, the incidence was lower in the extension trial compared with the pivotal trial (42.1% versus 84.2%).Major adverse cardiovascular events occurred in 2 patients (sudden cardiac death and coronary artery bypass graft).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.028208

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 140

Metadata

Authors
Blom, D. J., Averna, M. R., Meagher, E. A., du Toit Theron, H., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Larrey, D., Bloedon, L. T., Foulds, P., Rader, D. J., & Cuchel, M.
Venue
Circulation
Published
2017-07-18
Volume
136
Issue
3
Pages
332-335
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2734434515
Cited by
140
References
1
FWCI
13.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. https://app.cochat.ai/papers/10.1161/circulationaha.117.028208
The paper
Blom, D. J., Averna, M. R., Meagher, E. A., du Toit Theron, H., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Larrey, D., Bloedon, L. T., Foulds, P., Rader, D. J., & Cuchel, M. (2017). Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia. Circulation. https://doi.org/10.1161/circulationaha.117.028208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.